Market Overview

Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval

Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval

Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing.

Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine and Tenofovir Disoproxil Fumarate tablets, has received tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief, or PEPFAR.

Tentative FDA Approval For HIV Treatment

TLD is an antiretroviral fixed-dose combination, with the drug to be made available in developing countries as a first-line regimen for people being treated for HIV/AIDS.

Mylan clarified that TLD combines molecules from three originator medicines, namely ViiV Healthcare's Tivicay, which is licensed through the Medicines Patent Pool, Eprivir and GLD's Viread.

Pricing Pressure

Meanwhile, analyst David Risinger said the price pressure is worse than expected, as evidenced by Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) guidance reduction on Aug. 3. The analyst indicated that the two key consortiums causing the current pressure were ClarusONE and WBAD.

Giving details, the firm noted that ClarusOne, the buying consortium of McKesson Corporation (NYSE: MCK) and Wal-Mart Stores Inc (NYSE: WMT), had begun implementing lower priced contracts in the second quarter. With Express Scripts Holding Company (NASDAQ: ESRX)/Econdisc joining the Walgreens Boots Alliance Inc (NASDAQ: WBA) Development generic buying consortium on May 18, the firm believes lower pricing could start to hit Mylan in the second half of 2017.

See also: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Reducing Estimates, Price Target

The firm lowered its 2017 earnings per share estimate by 5 percent from $5.17 to $4.93 and its 2018 estimate by 10 percent from $5.78 to $5.21. The 2017 revenue estimate was lowered by 2 percent from $12.29 billion to $12.06 billion and the 2018 estimate was slashed by 4 percent from $13 billion to $12.4 billion.

The firm also trimmed its second quarter earnings per share and revenue estimates to $1.15 and $2.92 billion, respectively, both of which are below the consensus estimates.

Morgan Stanley maintains its Equal-Weight rating on the shares of Mylan, citing the low valuation, but lowered its price target for the shares from $52 to $36.

At time of writing, Mylan shares were down 2.64 percent at $32.05.

Latest Ratings for MYL

Jun 2019Initiates Coverage OnOverweight
May 2019DowngradesOutperformMarket Perform
Mar 2019Initiates Coverage OnBuy

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration FDA Analyst Ratings Best of Benzinga


Related Articles (ESRX + MCK)

View Comments and Join the Discussion!

Last Week In The S&P 500: Russell Weakness Bleeds Into The High Caps

Every Generation Has Its Drug: How People Are Dealing With Opioids, The New (Old) Thing